On May 28, 2019 Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, reported that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company and updates concerning its clinical stage drug candidates, momelotinib and SRA737, at 8:00 am ET on Wednesday, June 5 at the Jefferies Global Healthcare Conference being held in New York (Press release, Sierra Oncology, MAY 28, 2019, View Source [SID1234536605]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Dr. Glover will discuss:

updated progress in the development program for momelotinib, the company’s Phase 3 JAK1, JAK2 and ACVR1 inhibitor for the treatment of myelofibrosis.
preliminary clinical efficacy data for Sierra’s Chk1 inhibitor, SRA737, which will have been presented on June 1st at the 2019 ASCO (Free ASCO Whitepaper) Annual Meeting.
A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com.